Fireside Chat: Building Innovation Ecosystems, Not Just Pipelines

Session details:

How are companies identifying priority disease areas that align with internal discovery, business development and academic collaboration to advance the most promising science? Christelle Huguet, PhD, Executive Vice President, Global Head of R&D at Ipsen will discuss mergers & acquisitions, licensing deals and direct investments that help to drive innovation in rare liver diseases and oncology.

• The role of patient communities and patients as essential parts of the broader innovation network, not only as the end beneficiaries, but as contributors who help inform research priorities, define meaningful outcomes and shape approaches to long-term R&D planning.
• Executive point of view on strategy, including how scientific priorities, external innovation and planning, come together to support R&D growth.
• The model that Ipsen has identified and deployed is replicable across different therapeutic areas, demonstrating a scalable, sustainable opportunity for growth, translating insights into scientific and strategic decisions.